Trial Profile

A Phase 1 Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 04 Jul 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Azacitidine (Primary) ; Azacitidine (Primary) ; LY 3410738 (Primary) ; Venetoclax (Primary) ; Venetoclax (Primary)
Indications Acute myeloid leukaemia; Chronic myelomonocytic leukaemia; Myelodysplastic syndromes; Myeloproliferative disorders
Focus Adverse reactions; First in man; Therapeutic Use
Sponsors Eli Lilly and Company

Most Recent Events

27 Jun 2025 Planned End Date changed from 1 May 2025 to 1 May 2026.
04 Jun 2024 Planned End Date changed from 1 May 2024 to 1 May 2025.
30 May 2023 Planned primary completion date changed from 1 May 2024 to 1 Aug 2023.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com